+

WO2006009960A3 - Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants - Google Patents

Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2006009960A3
WO2006009960A3 PCT/US2005/021678 US2005021678W WO2006009960A3 WO 2006009960 A3 WO2006009960 A3 WO 2006009960A3 US 2005021678 W US2005021678 W US 2005021678W WO 2006009960 A3 WO2006009960 A3 WO 2006009960A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
hdacs
modifiers
modulators
Prior art date
Application number
PCT/US2005/021678
Other languages
English (en)
Other versions
WO2006009960A2 (fr
Inventor
Helen Francis-Lang
Kyle Andrew Edgar
Monique Nicoll
Original Assignee
Exelixis Inc
Helen Francis-Lang
Kyle Andrew Edgar
Monique Nicoll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Helen Francis-Lang, Kyle Andrew Edgar, Monique Nicoll filed Critical Exelixis Inc
Publication of WO2006009960A2 publication Critical patent/WO2006009960A2/fr
Publication of WO2006009960A3 publication Critical patent/WO2006009960A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Des gènes humains HDAC sont identifiés comme des modulateurs de la voie conductrice RB et sont de ce fait des cibles thérapeutiques en cas de troubles associés à la fonction RB défectueuse. L'invention concerne aussi des procédés pour identifier les modulateurs de RB, qui comprennent le criblage d'agents qui modulent l'activité de HDAC.
PCT/US2005/021678 2004-06-21 2005-06-20 Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants WO2006009960A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58168104P 2004-06-21 2004-06-21
US60/581,681 2004-06-21

Publications (2)

Publication Number Publication Date
WO2006009960A2 WO2006009960A2 (fr) 2006-01-26
WO2006009960A3 true WO2006009960A3 (fr) 2006-08-17

Family

ID=35785739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021678 WO2006009960A2 (fr) 2004-06-21 2005-06-20 Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants

Country Status (1)

Country Link
WO (1) WO2006009960A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134418A2 (fr) * 2008-04-30 2009-11-05 Fox Chase Cancer Center Dosage permettant l'identification d'agents modulant le silençage épigénétique et agents ainsi identifiés
US20150101999A1 (en) * 2013-10-11 2015-04-16 Diane WEST Hanger and a method of hanging articles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
WO2002102323A2 (fr) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Nouvelles histones deacetylases humaines
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2002102323A2 (fr) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Nouvelles histones deacetylases humaines
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease

Also Published As

Publication number Publication date
WO2006009960A2 (fr) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2003083047A3 (fr) Genes mp53 en tant que modificateurs de la voie des proteines p53 et methodes d'utilisation
WO2005016287A3 (fr) Prkwnk utilises en tant que modificateurs de la voie rac et methodes d'utilisation associees
WO2003051905A3 (fr) Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes
WO2006009947A3 (fr) Migfs utiles comme modificateurs du mecanisme d'action d'igf et leurs procedes d'utilisation
WO2004013309A3 (fr) Papss comme modificateurs de la voie d'axin et procédés d'utilisation
WO2004024882A3 (fr) Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes
WO2006009928A3 (fr) Galnts comme modificateurs du chemin igfr et procedes d'utilisation
WO2005072475A3 (fr) Itpks modificateurs de la voie igfr et procedes d'utilisation
WO2006009960A3 (fr) Hdac utilises comme modificateurs de la voie conductrice de rb et procedes d'utilisation correspondants
WO2004014301A3 (fr) Genes psmc utilises comme modificateurs du trajet retiniblastome (rb) et techniques d'utilisation
WO2006036613A3 (fr) Genes mrac utilises en tant que modificateurs de la voie rac et procedes d'utilisation correspondants
EP1723415A4 (fr) Genes pde servant de modificateurs de la voie igfr et leurs methodes d'utilisation
WO2007058860A3 (fr) Agents de modification des proteines rho utilises en tant qu'agents de modification du passages des rho et procedes d'utilisation associes
WO2005090992A3 (fr) Genes mpten modifiant le trajet pten, et procedes d'utilisation
WO2008036422A3 (fr) Vipr1 comme modificateurs de la voie e2f/rb et procédés d'utilisation
WO2007002081A3 (fr) Gfats utilises comme modificateurs de la voie de l axine et leurs procedes d'utilisation
WO2004048541A3 (fr) Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
WO2004015071A3 (fr) Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
WO2005017123A3 (fr) Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation
WO2004083389A3 (fr) Genes mbcat utilises comme modificateurs de la voie de la beta-catenine et techniques d'utilisation
WO2003074725A3 (fr) Mbcat comme modificateurs du mecanisme d'action de la $g(b)-catenine et procedes d'utilisation correspondants
WO2004061123A3 (fr) Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation
WO2004048538A3 (fr) Caseine kinases modifiant la voie rac et leurs procedes d'utilisation
WO2004083447A3 (fr) Mbcat en tant que modificateurs de la voie de la beta-catenine et methodes d'utilisation
WO2005003306A3 (fr) Sppls utilises en tant que modificateurs de la voie p53 et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载